Shewchuk A B, Corenblum B, Pairaudeau N, Ezrin C, Adamson G D
Am J Obstet Gynecol. 1980 Mar 1;136(5):652-8. doi: 10.1016/0002-9378(80)91019-4.
Adenohypophyseal function was evaluated in 20 consecutive patients with hyperprolactinemic amenorrhea-galactorrhea in an attempt to predict ovulatory response with 2-brom-alpha-ergocryptine (CB-154) therapy. Pituitary fossa tomography and response to insulin, thyrotropin-releasing hormone, and luteinizing hormone--releasing hormone were correlated with the return of ovulatory cycles. Fourteen of 15 patients demonstrating normal pretreatment sellar volume ovulated, compared with 0 of 5 showing increased volume. Thirteen of 14 with adequate adenophypophyseal reserve of growth hormone and luteinizing hormone ovulated, compared with 0 of 6 and 1 of 6, respectively, with inadequate reserve. Serum prolactin suppression to normal occurred in 19 of 20 patients but could not predict response. Only 2 of 10 patients receiving clomiphene citrate ovulated and neither conceived, while 8 of the 10 ovulated with CB-154 and 6 of 7 desiring pregnancy conceived. CB-154 is an effective "fertility drug" and response to therapy can usually be predicted.
对20例高催乳素血症性闭经-溢乳患者的腺垂体功能进行了评估，以试图预测用2-溴-α-麦角隐亭（CB-154）治疗后的排卵反应。垂体窝断层扫描以及对胰岛素、促甲状腺激素释放激素和促黄体生成素释放激素的反应与排卵周期的恢复相关。15例治疗前蝶鞍容积正常的患者中有14例排卵，而5例蝶鞍容积增大的患者中无1例排卵。14例生长激素和促黄体生成素腺垂体储备充足的患者中有13例排卵，而储备不足的6例患者中分别无1例和仅有1例排卵。20例患者中有19例血清催乳素被抑制至正常水平，但这并不能预测反应。接受枸橼酸氯米芬治疗的10例患者中仅有2例排卵，且均未受孕，而10例接受CB-154治疗的患者中有8例排卵，7例有妊娠意愿的患者中有6例受孕。CB-154是一种有效的“生育药物”，通常可以预测治疗反应。
